Biosimilar Uptake EU: Market Impact Post-Patent Expirations & HTA Regulation

Key Takeaways

The European Union faces a critical biosimilar development gap as nearly 100 biologic drugs approach patent expiration by 2032, with 79% lacking biosimilar candidates in development pipelines. This shortfall—particularly acute for low-sales biologics and rare disease treatments—threatens to undermine cost-containment efforts across EU healthcare systems and represents an estimated $143 billion in missed market opportunities. Why it matters: The absence of biosimilar competition for most expiring biologics will likely perpetuate high drug costs and limit patient access to affordable biologic therapies in an era of constrained healthcare budgets.

Market Landscape: The Biosimilar Pipeline Crisis

The EU biosimilar market faces a structural imbalance that threatens both healthcare affordability and industry innovation. As the patent protection for approximately 100 biologic medicines expires between now and 2032, the biosimilar development pipeline remains severely underpopulated. The data reveals a troubling disparity: while high-sales biologics attract biosimilar developers seeking substantial market opportunities, low-sales and orphan biologics face competitive neglect.

The 79% figure—representing biologics without biosimilars currently in development—underscores a market failure where economics, regulatory complexity, and manufacturing barriers converge to discourage biosimilar investment in less profitable segments. This gap is not randomly distributed. Molecules with annual sales below €500 million at patent expiry experience the most acute shortage, with 76% facing zero biosimilar competition. For rare disease biologics, the situation is equally concerning, as smaller patient populations and limited commercial incentives further discourage biosimilar development.

Economic Implications and the $143 Billion Opportunity Cost

The $143 billion in estimated missed market opportunities represents more than a theoretical loss—it reflects real constraints on healthcare budgets and patient access across Europe. This figure encompasses both direct savings from biosimilar price competition and indirect benefits such as expanded treatment capacity, improved adherence through affordability, and reallocation of healthcare resources to underserved populations.

Compared with high-income markets like the United States, where biosimilar penetration has accelerated post-FDA biosimilar approval pathways, the EU's fragmented regulatory landscape and variable HTA requirements across member states create additional barriers. Each EU5 market—Germany, France, Italy, Spain, and the United Kingdom—operates distinct reimbursement frameworks, forcing biosimilar developers to navigate multiple approval and pricing negotiations simultaneously. This regulatory burden disproportionately affects developers of low-sales biologics, where the return on investment may not justify the compliance costs.

Regulatory Context: EMA's Role and HTA Frameworks

The European Medicines Agency (EMA) maintains a well-established biosimilar approval pathway under the centralized procedure, which has successfully enabled market entry for biosimilars of high-profile originator biologics. However, the regulatory framework alone cannot overcome the economic disincentives facing biosimilar developers targeting low-sales or rare disease biologics.

The EMA's existing incentive structures—including data exclusivity, market exclusivity periods, and accelerated assessment pathways—are calibrated for molecules with substantial commercial potential. For rare disease biologics, orphan drug designation provides market exclusivity but does not eliminate the underlying economic constraints of small patient populations. The absence of tailored regulatory pathways or enhanced incentives specifically designed for low-sales biosimilars represents a gap in EMA policy.

Health Technology Assessment bodies across the EU compound this challenge. HTA agencies in France, Germany, and other member states evaluate biosimilars against originator biologics using comparative clinical efficacy frameworks. While these assessments protect patient safety, they can delay biosimilar market entry and complicate pricing negotiations, particularly when HTA bodies require head-to-head clinical trial data rather than accepting pharmacokinetic/pharmacodynamic equivalence evidence.

Competitive Dynamics: High-Sales vs. Low-Sales Biologics

The biosimilar market exhibits a pronounced bifurcation. High-sales biologics—such as those in oncology, immunology, and cardiovascular disease—attract multiple biosimilar developers and achieve rapid market penetration post-patent expiration. These molecules generate sufficient revenue to justify the €100–150 million development and regulatory costs associated with biosimilar programs.

Conversely, low-sales biologics and rare disease treatments face biosimilar developer indifference. A biologic with €300–400 million in annual sales cannot support the same development costs and timeline as a blockbuster therapy. Additionally, smaller patient populations create uncertainty regarding post-launch market share and revenue projections, further depressing investment appetite.

This dynamic creates a two-tiered market: patients with common diseases benefit from biosimilar competition and price reductions, while patients with rare diseases or those dependent on lower-volume biologics remain exposed to originator pricing power indefinitely. The equity implications are substantial, particularly across lower-income EU member states where healthcare budgets are constrained.

Future Outlook: Addressing the Pipeline Gap

What to watch next: The EU pharmaceutical landscape will likely evolve through targeted policy interventions aimed at incentivizing biosimilar development for underserved segments. Several pathways merit monitoring.

Regulatory innovation: The EMA may introduce expedited pathways or reduced data requirements for biosimilars targeting rare disease biologics. Such measures would lower development costs and timelines, potentially making low-sales biosimilar programs economically viable. The European Commission's ongoing pharmaceutical legislation reform presents an opportunity to embed these incentives into formal regulatory frameworks.

Collaborative development models: Public-private partnerships, government-backed biosimilar development initiatives, and academic-industry consortia may emerge to address the pipeline gap. Some EU member states have explored government-funded biosimilar development for orphan biologics, though scaling such programs remains challenging.

HTA harmonization: Greater standardization of HTA requirements across EU5 markets could reduce the regulatory burden on biosimilar developers. Mutual recognition of pharmacokinetic/pharmacodynamic equivalence data across member states would streamline approvals and reduce costs, particularly benefiting low-sales biosimilar programs.

Pricing and reimbursement strategies: Innovative payment models—such as value-based pricing for biosimilars, tiered pricing aligned with patient populations, or risk-sharing agreements—may improve the commercial viability of low-sales biosimilar programs.

Post-2030, as the first wave of patent expirations occurs, market dynamics will reveal whether these interventions succeed or whether the biosimilar pipeline gap persists. Healthcare systems unprepared for biosimilar competition in low-sales segments may face continued budget pressures, while developers who successfully navigate the regulatory complexity of rare disease biosimilars will capture significant first-mover advantages.

Frequently Asked Questions

References

1. Analysis of EU biologic patent expirations and biosimilar pipeline development (2024). Data on approximately 100 biologics losing patent protection by 2032 in the EU, with 79% lacking biosimilars in development; 76% of molecules with annual sales below €500 million at patent expiry facing no biosimilar competition; and estimated $143 billion missed market opportunity due to lack of biosimilar competition.